Search results

Tell us about an interventional procedure you think should be assessed by NICE.

Home What NICE does NICE International {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1

If you’re unsure where to start or your circumstances are unique, we encourage you to get in touch. We’ll work with you to unpick your challenges and find a solution that meets your needs.

The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

An approximate guide to the timings for the development of a piece of HealthTech guidance.

Our Medical Technologies Evaluation Programme (MTEP) considers technologies that could offer benefits to patients and the health and social care system over current practice.

Our Medical Technologies Evaluation Programme (MTEP) evaluates new HealthTech.

We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.

Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.

NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.

Home What NICE does Our guidance About technology appraisal guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":

Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.

Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

NICE priority methodological research areas.